Cylindroma

Back

Background

Cylindromas are benign skin appendage tumors. They can be seen in conjunction with spiradenomas and trichoepitheliomas. Cases of spiradenocylindromas, demonstrating characteristics of both spiradenoma and cylindroma in the same tumor mass, have also been observed, suggesting similar derivation of both tumors.

They most commonly occur on the head and neck as solitary or multiple tumors. Solitary cylindromas occur sporadically and typically are not inherited. Multiple tumors are observed in an autosomal dominantly inherited manner. When nodules enlarge and coalesce on the scalp, they form the distinctive turban tumor feature.

Malignant cylindromas are very rare. Malignant transformation may develop within solitary cylindromas, or they may complicate the multiple variant (more common).

Pathophysiology

Cylindromas are appendage tumors previously thought to be of apocrine differentiation. While phenotypic features differ between cylindromas and spiradenomas, recent studies have shown immunohistological and cytomorphological overlap, with both tumors exhibiting apocrine, eccrine, secretory, and ductal features. Therefore, the cellular origin of cylindromas remains unknown. Cylindromas are most likely a very primitive sweat gland tumor differentiating toward either the eccrine or apocrine line.

Brooke-Spiegler syndrome (BSS) has been described as an autosomal dominant disease characterized by the development of multiple skin appendage tumors such as cylindromas, trichoepitheliomas, and spiradenomas, with a variable preponderance of any of the aforementioned subsets. Other lesions reported with BSS include parotid basal cell adenomas, organoid nevi, syringomas, and basal cell carcinomas. Despite variable phenotypic expressions of a predominant tumor in BSS, the gene responsible for multiple cylindromas, CYLD, is localized to band 16q12-q13. The mechanism of genotypic similarity and phenotypic variance is not yet understood.[1, 2]

In 2006, Zhang et al[3] reported a large consanguineous Chinese family with BSS demonstrating intrafamily phenotypic variability. Upon examination, some persons only manifested discrete, small, skin-coloured growths, while the proband manifested an expansion of multiple large growths on the nose and numerous dome-shaped papules on the scalp. Biopsy showed both trichoepitheliomas and cylindromas in the affected persons. By sequence analysis, Zhang et al identified a recurrent mutation 2272C→T (R758X) of the CYLD gene in the affected familial persons that had been previously identified in other ethnic kindreds with familial cylindromatosis.

In 2007, Stegmeier et al[4] noted that the CYLD gene encodes a deubiquitinating enzyme. The enzyme removes Lys-63–linked ubiquitin chains from I-kappaB kinase signaling components. By this mechanism, the enzyme inhibits NF-kappaB pathway activation. They demonstrated that CYLD is also required for the cell's timely entry into mitosis. Consistent with a cell-cycle regulatory function, CYLD localizes to microtubules in interphase and the midbody during telophase. CYLD 's protein levels decrease as cells exit from mitosis. Stegmeier et al identified the protein kinase Plk1 as a potential target of CYLD as a regulator of mitotic entry, and they suggested this because of the physical interaction and similar loss-of-function and over-expression phenotypes.

These findings raise the possibility that, as with other genes that regulate tumorigenesis, CYLD has both tumor-suppressing (apoptosis regulation) and tumor-promoting activities (enhancer of mitotic entry). They suggested that this additional function of CYLD could provide an explanation for the benign nature of most cylindroma lesions.

Massoumi and Paus[5] and explained the manner in which CYLD interferes with tumor necrosis factor-alpha or Toll-like receptor–mediated signaling and with JNK or NF-kappaB-dependent p65/50 signaling to limit inflammation. Additionally, the manner by which CYLD interferes with activation of the proto-oncogene BCL3 and with cyclin D1 expression to limit tumorigenesis was also explained. Finally, the researchers discussed how tumor growth-promoting agents or UV light and inflammatory mediators may activate CYLD.

Researchers have noted a MYB-NFIB gene fusion, which provides a new genetic link between dermal cylindroma and adenoid cystic carcinoma.[6]

Epidemiology

Frequency

United States

Cylindromas are uncommon. The exact incidence is not known.

International

The exact international incidence of cylindromas is not known.

Mortality/Morbidity

Most cylindromas remain benign; however, at least 14 reports have described malignant transformation. Multiple cylindromas can cover the entire scalp and cause the disfiguring turban tumor appearance, which necessitates extensive reconstructive surgery.

Race

No racial disparity is reported for cylindromas.

Sex

The incidence of cylindroma is more common in females than in males. Female-to-male ratios of 6:1 and 9:1 have been reported.

Age

Solitary cylindromas are lesions that affect middle-aged and elderly persons. Multiple, inherited cylindromas usually begin in early adulthood and increase in size and number throughout life.

History

Physical

Except for BSS, pertinent findings are largely limited to the skin. Histologically similar tumors have been found in the breast, parotid glands, salivary glands, lacrimal gland of the eye, Bartholin glands, the brain, lungs, and kidneys.

Causes

The cause of sporadic, solitary cylindromas is largely unknown; however, genetic studies of sporadic cylindromas show loss of heterozygosity at and around the CYLD locus in a substantial number of cases, suggesting that this gene also plays a role in the development of sporadic tumors.

The tyrosine kinase pathway might be a treatment target in tumors with defective CYLD.[10]

Familial cylindromatosis is inherited in an autosomal dominant fashion, and the responsible gene, CYLD, is located on band 16q12-13. Tumors exhibit loss of heterozygosity, implicating the gene as a tumor suppressor gene.

Procedures

A skin biopsy may be performed. Light microscopy with ordinary hematoxylin and eosin (H&E) staining is sufficient for diagnosis of cylindroma.

Histologic Findings

Cylindroma is a dermal tumor without attachment to the epidermis. The lesion is composed of numerous oval and polygonal nests molded into a jigsawlike pattern. Masses of epithelial cells are surrounded and penetrated by a hyaline sheath closely resembling a basement membrane. This sheath separates the tumor from the dermal mesenchyme, yet does not interfere with tumor growth and proliferation.

Malignant cylindromas demonstrate islands of cells displaying marked anaplasia and pleomorphism of nuclei. Mitoses are increased and are abnormal. Besides invasion into surrounding tissue, loss of the delicate hyaline sheath occurs.

Tumor islands are composed of 2 cell types. Peripheral cells are small and highly basophilic; palisading is suggested. Larger, more pale-staining cells are seen centrally. Small tubal lumina are sometimes found with careful observation.

A lack of lymphoid tissue is a histological feature that differentiates cylindromas from spiradenomas. Spiradenomas show a unique prominent presence of lymphocytes. Cylindromas, on the other hand, demonstrate a large number of prominent dendritic cells that most likely represent Langerhans cells that permeate the tumor. S-100 protein–, HLA-DR–, and CD1a-positive cells can be seen in cylindromas and represent the existence of Langerhans cells.

Hyaline bands, which surround tumor islands, are mostly composed of type IV collagen. This is equivalent to the subepidermal lamina densa. Fragments of anchoring fibrils, identical to type VII collagen, are also seen. These anchoring fibrils can also be seen embedded in basement membrane on electron microscopy (EM).

The hyaline membrane is highly enlarged compared with the dermoepidermal junction, as observed by EM. EM demonstrates a basement membrane of 2.7-4.3 µm, compared with the dermoepidermal junction average basement membrane thickness of 60-90 nm. EM also demonstrates that cylindromas lack clear distinction of lamina densa. Numerous abnormal inclusions of fibrillar material are noted and appear similar to lamina lucida.

Although hemidesmosomes (HDs) are seen with EM, they are irregularly spaced and can only be seen in high power, compared with normal basal keratinocytes, in which HDs are seen at low power. HDs noted in the cylindroma cells have greater size variation and half the normal number of basal keratinocytes.

Immunohistochemical studies on cylindromas demonstrate a variation in cell matrix proteins compared with normal epidermal basal keratinocytes. Alpha-6-beta-4 integrin expression in tumor cells is weaker. In normal basal keratinocytes, laminin-5 is understood as necessary for HD and basement membrane formation. Further studies have shown an improper processing of laminin-5 in cylindromas. This may explain the lower percentage of HDs in cylindromas. Cylindromas also demonstrate low expression of alpha-6-beta-4 integrins. These changes may be the cause the structural abnormalities seen in the basement membranes of cylindromas.

Immunohistochemical analysis has demonstrated myoepithelial, apocrine, eccrine, ductal, and secretory features in both cylindromas and spiradenomas. Alpha-SMA, indicating myoepithelial differentiation, has been shown to be expressed in the basaloid cells of both tumors. Both tumors also demonstrate S-100 protein expression, a marker designating eccrine differentiation and apocrine markers, human milk fat globulin, and lysozyme. In addition, expression of keratin polypeptides 10 and 14, specific for ductal epithelium, and keratins 7, 8, and 18, specific for secretory cells, have been observed in both cylindromas and spiradenomas.

Nerve growth factor, S-100 protein, CD44, and CD34 are other markers that have been found to be expressed in or surrounding eccrine coils and are not expressed in the eccrine duct or apocrine gland. These markers have all been found to varying degrees in cylindromas. Other immunohistochemical studies linking cylindromas to eccrine differentiation include positive expression of cytokeratins 19 and 1/10/11. IKH-4 is a monoclonal antibody specific for the eccrine gland and will not stain apocrine glands. This marker can also be used to differentiate eccrine from apocrine tumors and is positive in eccrine cylindromas and spiradenomas.[12]

Immunohistochemical studies linking cylindromas to apocrine differentiation include the expression of alpha-1-antichymotrypsin, alpha smooth muscle actin (1A4), and cytokeratins 8 and 18.

Staining for cytokeratin 15, a marker specific for hair follicle stem cells, has also been shown in some cylindromas and spiradenomas. The expression of follicular, apocrine, and eccrine features in cylindromas suggests that the tumor may be derived from epithelial stem cells of immature differentiation.

Markers expressed in cylindromas and both eccrine and apocrine glands include epithelial membrane antigen, carcinoembryonic antigen, mucinlike carcinoma-associated antigen (B12), laminin, collagen IV, fibronectin, and CD34(QBEND/10).

Surgical Care

Further Outpatient Care

Follow-up care of patients with multiple cylindromas is recommended because of the tendency for new lesions to develop. Follow-up care is also recommended because of the risk of malignant degeneration.

Complications

A cylindroma occasionally erodes through the skull, causing hemorrhage and meningitis.

Anal and rectal spiradenocylindroma-like basaloid carcinomas have been reported with CYLD gene mutations defined.[15]

Scattered reports exist of malignant transformation of isolated cylindromas, so this must be a consideration for regular follow-up for patients with cylindromas.[16]

Prognosis

The prognosis is not good with malignancy because visceral metastasis frequently follows.

Author

Noah S Scheinfeld, MD, JD, FAAD, Assistant Clinical Professor, Department of Dermatology, Columbia University College of Physicians and Surgeons; Consulting Staff, Department of Dermatology, St Luke's Roosevelt Hospital Center, Beth Israel Medical Center, and New York Eye and Ear Infirmary; Private Practice

Disclosure: Optigenex Consulting fee Independent contractor

Coauthor(s)

Anusuya Mokashi, MD, MS, Resident Physician, Department of Radiology, Staten Island University Hospital

Disclosure: Nothing to disclose.

Arnold R Oppenheim, MD, Assistant Professor, Department of Internal Medicine, Division of Dermatology, Eastern Virginia School of Medicine

Disclosure: Nothing to disclose.

Julide Tok Celebi, MD, Assistant Professor of Dermatology, Columbia University, College of Physicians and Surgeons; Consulting Staff, Department of Dermatology, New York Presbyterian Medical Center

Disclosure: Nothing to disclose.

Specialty Editors

Abby S Van Voorhees, MD, Assistant Professor, Director of Psoriasis Services and Phototherapy Units, Department of Dermatology, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania

Disclosure: Amgen Honoraria Consulting; Abbott Honoraria Consulting; Merck Salary Management position; Abbott Honoraria Speaking and teaching; Amgen Honoraria Review panel membership; Centocor Honoraria Consulting; Leo Consulting; Merck None Other

Richard P Vinson, MD, Assistant Clinical Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Disclosure: Nothing to disclose.

Christen M Mowad, MD, Associate Professor, Department of Dermatology, Geisinger Medical Center

Disclosure: Nothing to disclose.

Joel M Gelfand, MD, MSCE, Medical Director, Clinical Studies Unit, Assistant Professor, Department of Dermatology, Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania

Disclosure: AMGEN Consulting fee Consulting; AMGEN Grant/research funds Investigator; Genentech Grant/research funds investigator; Centocor Consulting fee Consulting; Abbott Grant/research funds investigator; Abbott Consulting fee Consulting; Novartis investigator; Pfizer Grant/research funds investigator; Celgene Consulting fee DMC Chair; NIAMS and NHLBI Grant/research funds investigator

Chief Editor

Dirk M Elston, MD, Director, Ackerman Academy of Dermatopathology, New York

Disclosure: Nothing to disclose.

References

  1. Bignell GR, Warren W, Seal S, et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet. Jun 2000;25(2):160-5. [View Abstract]
  2. Bowen S, Gill M, Lee DA, et al. Mutations in the CYLD gene in Brooke-Spiegler syndrome, familial cylindromatosis, and multiple familial trichoepithelioma: lack of genotype-phenotype correlation. J Invest Dermatol. May 2005;124(5):919-20. [View Abstract]
  3. Zhang G, Huang Y, Yan K, et al. Diverse phenotype of Brooke-Spiegler syndrome associated with a nonsense mutation in the CYLD tumor suppressor gene. Exp Dermatol. Dec 2006;15(12):966-70. [View Abstract]
  4. Stegmeier F, Sowa ME, Nalepa G, Gygi SP, Harper JW, Elledge SJ. The tumor suppressor CYLD regulates entry into mitosis. Proc Natl Acad Sci U S A. May 22 2007;104(21):8869-74. [View Abstract]
  5. Massoumi R, Paus R. Cylindromatosis and the CYLD gene: new lessons on the molecular principles of epithelial growth control. Bioessays. Dec 2007;29(12):1203-14. [View Abstract]
  6. Fehr A, Kovács A, Löning T, Frierson H Jr, van den Oord J, Stenman G. The MYB-NFIB gene fusion-a novel genetic link between adenoid cystic carcinoma and dermal cylindroma. J Pathol. Jul 2011;224(3):322-7. [View Abstract]
  7. Fukuda M, Hiroi M, Suzuki S, Ohmori Y, Sakashita H. Loss of CYLD might be associated with development of salivary gland tumors. Oncol Rep. Jun 2008;19(6):1421-7. [View Abstract]
  8. Parren LJ, Bauer B, Hamm H, Frank J. Brooke-Spiegler syndrome complicated by unilateral hearing loss. Int J Dermatol. Nov 2008;47 Suppl 1:56-9. [View Abstract]
  9. Carlson RM, Haddad L, Pui JC. Brooke-Spiegler syndrome with associated pegged teeth. Cutis. Nov 2008;82(5):345-9. [View Abstract]
  10. Rajan N, Elliott R, Clewes O, et al. Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours. Oncogene. May 9 2011;[View Abstract]
  11. Vranic S, Bender R, Palazzo J, Gatalica Z. A review of adenoid cystic carcinoma of the breast with emphasis on its molecular and genetic characteristics. Hum Pathol. Apr 18 2012;[View Abstract]
  12. Ishihara M, Mehregan DR, Hashimoto K, et al. Staining of eccrine and apocrine neoplasms and metastatic adenocarcinoma with IKH-4, a monoclonal antibody specific for the eccrine gland. J Cutan Pathol. Feb 1998;25(2):100-5. [View Abstract]
  13. Rallan D, Harland CC. Brooke-Spiegler syndrome: treatment with laser ablation. Clin Exp Dermatol. Jul 2005;30(4):355-7. [View Abstract]
  14. Retamar RA, Stengel F, Saadi ME, et al. Brooke-Spiegler syndrome - report of four families: treatment with CO2 laser. Int J Dermatol. Jun 2007;46(6):583-6. [View Abstract]
  15. Kacerovska D, Szepe P, Vanecek T, et al. Spiradenocylindroma-like basaloid carcinoma of the anus and rectum: case report, including HPV studies and analysis of the CYLD gene mutations. Am J Dermatopathol. Oct 2008;30(5):472-6. [View Abstract]
  16. Bansal C, Batra M, Lal N, Srivastava AN. Solitary cylindroma with malignant transformation. Indian J Dermatol. Mar 2012;57(2):141-3. [View Abstract]
  17. Albores-Saavedra J, Heard SC, McLaren B, Kamino H, Witkiewicz AK. Cylindroma (dermal analog tumor) of the breast: a comparison with cylindroma of the skin and adenoid cystic carcinoma of the breast. Am J Clin Pathol. Jun 2005;123(6):866-73. [View Abstract]
  18. Berberian BJ, Sulica VI, Kao GF. Familial multiple eccrine spiradenomas with cylindromatous features associated with epithelioma adenoides cysticum of Brooke. Cutis. Jul 1990;46(1):46-50. [View Abstract]
  19. Biernat W, Biernat S. Cutaneous adnexal carcinoma arising within a solitary cylindroma-spiradenoma. Am J Dermatopathol. Feb 1996;18(1):77-82. [View Abstract]
  20. Biggs PJ, Chapman P, Lakhani SR, Burn J, Stratton MR. The cylindromatosis gene (cyld1) on chromosome 16q may be the only tumour suppressor gene involved in the development of cylindromas. Oncogene. Mar 21 1996;12(6):1375-7. [View Abstract]
  21. Cardenas AA, Norton SA, Fitzpatrick JE. Solitary violaceous nodule on the face. Dermal cylindroma (also known as cylindroma, dermal eccrine cylindroma, Spiegler's tumor, turban tumor, and tomato tumor). Arch Dermatol. Apr 1993;129(4):498-9, 501. [View Abstract]
  22. Choi HR, Batsakis JG, Callender DL, Prieto VG, Luna MA, El-Naggar AK. Molecular analysis of chromosome 16q regions in dermal analogue tumors of salivary glands: a genetic link to dermal cylindroma?. Am J Surg Pathol. Jun 2002;26(6):778-83. [View Abstract]
  23. Chu L, Gu J, He Z, Xiao T, Liu X. Adenoviral vector expressing CYLD augments antitumor activity of TRAIL by suppression of NF-kappaB survival signaling in hepatocellular carcinoma. Cancer Biol Ther. Jun 2006;5(6):615-22. [View Abstract]
  24. De Francesco V, Frattasio A, Pillon B, et al. Carcinosarcoma arising in a patient with multiple cylindromas. Am J Dermatopathol. Feb 2005;27(1):21-6. [View Abstract]
  25. Ferrándiz C, Campo E, Baumann E. Dermal cylindromas (turban tumour) and eccrine spiradenomas in a patient with membranous basal cell adenoma of the parotid gland. J Cutan Pathol. Feb 1985;12(1):72-9. [View Abstract]
  26. Fukuda M, Fukuda F, Horiuchi Y, et al. Expression of CYLD, NF-kappaB and NF-kappaB-related factors in salivary gland tumors. In Vivo. Jul-Aug 2006;20(4):467-72. [View Abstract]
  27. Galadari E, Mehregan AH, Lee KC. Malignant transformation of eccrine tumors. J Cutan Pathol. Feb 1987;14(1):15-22. [View Abstract]
  28. Gerber JE, Descalzi ME. Eccrine spiradenoma and dermal cylindroma. J Cutan Pathol. Feb 1983;10(1):73-8. [View Abstract]
  29. Gerretsen AL, Beemer FA, Deenstra W, Hennekam FA, van Vloten WA. Familial cutaneous cylindromas: investigations in five generations of a family. J Am Acad Dermatol. Aug 1995;33(2 Pt 1):199-206. [View Abstract]
  30. Gerretsen AL, van der Putte SC, Deenstra W, van Vloten WA. Cutaneous cylindroma with malignant transformation. Cancer. Sep 1 1993;72(5):1618-23. [View Abstract]
  31. Goette DK, McConnell MA, Fowler VR. Cylindroma and eccrine spiradenoma coexistent in the same lesion. Arch Dermatol. Apr 1982;118(4):274-4. [View Abstract]
  32. Gokaslan ST, Carlile B, Dudak M, Albores-Saavedra J. Solitary cylindroma (dermal analog tumor) of the breast: a previously undescribed neoplasm at this site. Am J Surg Pathol. Jun 2001;25(6):823-6. [View Abstract]
  33. Headington JT, Batsakis JG, Beals TF, Campbell TE, Simmons JL, Stone WD. Membranous basal cell adenoma of parotid gland, dermal cylindromas, and trichoepitheliomas. Comparative histochemistry and ultrastructure. Cancer. Jun 1977;39(6):2460-9. [View Abstract]
  34. Heinritz W, Grunewald S, Strenge S, et al. A case of Brooke-Spiegler syndrome with a new mutation in the CYLD gene. Br J Dermatol. May 2006;154(5):992-4. [View Abstract]
  35. Kazakov DV, Soukup R, Mukensnabl P, Boudova L, Michal M. Brooke-Spiegler syndrome: report of a case with combined lesions containing cylindromatous, spiradenomatous, trichoblastomatous, and sebaceous differentiation. Am J Dermatopathol. Feb 2005;27(1):27-33. [View Abstract]
  36. Kim C, Kovich OI, Dosik J. Brooke-Spiegler syndrome. Dermatol Online J. Jan 27 2007;13(1):10. [View Abstract]
  37. Lin PY, Fatteh SM, Lloyd KM. Malignant transformation in a solitary dermal cylindroma. Arch Pathol Lab Med. Aug 1987;111(8):765-7. [View Abstract]
  38. Lotem M, Trattner A, Kahanovich S, Rotem A, Sandbank M. Multiple dermal cylindroma undergoing a malignant transformation. Int J Dermatol. Sep 1992;31(9):642-4. [View Abstract]
  39. Martinez W, Yebra MT, Arnal F, Casado M, Borbujo J. Multiple linear cylindromas. J Am Acad Dermatol. May 1992;26(5 Pt 2):821-4. [View Abstract]
  40. Massoumi R, Podda M, Fassler R, Paus R. Cylindroma as tumor of hair follicle origin. J Invest Dermatol. May 2006;126(5):1182-4. [View Abstract]
  41. Meybehm M, Fischer HP. Spiradenoma and dermal cylindroma: comparative immunohistochemical analysis and histogenetic considerations. Am J Dermatopathol. Apr 1997;19(2):154-61. [View Abstract]
  42. Michal M, Lamovec J, Mukensnabl P, Pizinger K. Spiradenocylindromas of the skin: tumors with morphological features of spiradenoma and cylindroma in the same lesion: report of 12 cases. Pathol Int. May 1999;49(5):419-25. [View Abstract]
  43. Misago N, Inoue T, Narisawa Y. Subcutaneous epithelioid angiomatous nodule: a variant of epithelioid hemangioma. J Dermatol. Jan 2006;33(1):73-4. [View Abstract]
  44. Munger BL, Graham JH, Helwig EB. Ultrastructure and histochemical characteristics of dermal eccrine cylindroma (turban tumor). J Invest Dermatol. Dec 1962;39:577-95. [View Abstract]
  45. Nonaka D, Rosai J, Spagnolo D, Fiaccavento S, Bisceglia M. Cylindroma of the breast of skin adnexal type: a study of 4 cases. Am J Surg Pathol. Aug 2004;28(8):1070-5. [View Abstract]
  46. Novo-Torres A, Laredo-Ortiz C, Castellar-Najera E, Lorda-Barraguer E, Alenda-Gonzalez C. [Familial presentation of multiple scalp tumors]. Actas Dermosifiliogr. Mar 2007;98(2):109-11. [View Abstract]
  47. Oiso N, Mizuno N, Fukai K, Nakagawa K, Ishii M. Mild phenotype of familial cylindromatosis associated with an R758X nonsense mutation in the CYLD tumour suppressor gene. Br J Dermatol. Nov 2004;151(5):1084-6. [View Abstract]
  48. Penneys NS, Kaiser M. Cylindroma expresses immunohistochemical markers linking it to eccrine coil. J Cutan Pathol. Feb 1993;20(1):40-3. [View Abstract]
  49. Pfaltz M, Bruckner-Tuderman L, Schnyder UW. Type VII collagen is a component of cylindroma basement membrane zone. J Cutan Pathol. Dec 1989;16(6):388-95. [View Abstract]
  50. Rajan N, Burn J, Langtry J, Sieber-Blum M, Lord CJ, Ashworth A. Transition from cylindroma to spiradenoma in CYLD-defective tumours isassociated with reduced DKK2 expression. J Pathol. Mar 2011;[View Abstract]
  51. Scheinfeld N, Hu G, Gill M, Austin C, Celebi JT. Identification of a recurrent mutation in the CYLD gene in Brooke-Spiegler syndrome. Clin Exp Dermatol. Sep 2003;28(5):539-41. [View Abstract]
  52. Tellechea O, Reis JP, Ilheu O, Baptista AP. Dermal cylindroma. An immunohistochemical study of thirteen cases. Am J Dermatopathol. Jun 1995;17(3):260-5. [View Abstract]
  53. Tunggal L, Ravaux J, Pesch M, et al. Defective laminin 5 processing in cylindroma cells. Am J Pathol. Feb 2002;160(2):459-68. [View Abstract]
  54. Urbanski SJ, From L, Abramowicz A, Joaquin A, Luk SC. Metamorphosis of dermal cylindroma: possible relation to malignant transformation. Case report of cutaneous cylindroma with direct intracranial invasion. J Am Acad Dermatol. Jan 1985;12(1 Pt 2):188-95. [View Abstract]